Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | THRA | P10827 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15892524 | 0.93 | HPGD (0.59) | HPGDSMN1; SMN2THRATHRBTMEM97 | |
| SCHEMBL10076245 | 0.90 | ALDH1A1 (0.66) | HPGDSMN1; SMN2THRATHRBTMEM97 | |
| SCHEMBL10020214 | 0.90 | HPGD (0.79) | HPGDSMN1; SMN2THRATHRBTMEM97 | |
| SCHEMBL18667945 | 0.85 | POLB (0.64) | TMEM97SIGMAR1ALDH1A1PLK1NPC1 | |
| SCHEMBL8411545 | 0.84 | HPGD (0.70) | HPGDSMN1; SMN2THRATHRBTMEM97 | |
| SCHEMBL2120449 | 0.84 | HPGD (0.70) | HPGDSMN1; SMN2THRATHRBALDH1A1 | |
| SCHEMBL7507397 | 0.84 | PPARA (0.52) | HPGDSMN1; SMN2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL23840600 | 0.84 | HPGD (0.62) | HPGDSMN1; SMN2THRATHRBTMEM97 | |
| SCHEMBL6359262 | 0.83 | L3MBTL1 (0.63) | SMN1; SMN2ALDH1A1PLK1KDM4ENPC1 | |
| SCHEMBL13060861 | 0.83 | BCL2 (0.56) | HPGDSMN1; SMN2TMEM97SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | HPGD 2186/4885SMN1; SMN2 2561/4885THRA 3467/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | HPGD 274/4885SMN1; SMN2 1192/4885THRA 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.